Belvís, Robert
Irimia, Pablo
Pozo-Rosich, Patricia
González-Oria, Carmen
Cano, Antonio
Viguera, Javier
Sánchez, Belén
Molina, Francisco
Beltrán, Isabel
Oterino, Agustín
Cuadrado, Elisa
Gómez-Camello, Angel
Alberte-Woodward, Miguel
Jurado, Carmen
Oms, Teresa
Ezpeleta, David
de Terán, Javier Díaz
Morollón, Noemí
Latorre, Germán
Torres-Ferrús, Marta
Alpuente, Alicia
Lamas, Raquel
Toledano, Carlos
Leira, Rogelio
Santos, Sonia
del Río, Margarita Sánchez
Article History
Received: 28 February 2021
Accepted: 26 May 2021
First Online: 17 July 2021
Declarations
:
: MAB-MIG was classified as a <i>low-intervention clinical trial</i> by the Spanish Medicines Agency and Medical Devices and was approved by the Ethics Committee of Investigation with Medicines of the Health Area of Valladolid, Spain (PI 20–1790).
: Authors consent the publication of the paper MAB-MIG: REGISTRY OF THE SPANISH NEUROLOGICAL SOCIETY OF ERENUMAB FOR MIGRAINE PREVENTION. THREE-MONTHS RESULTS in The Journal of Headache and Pain.
: Within the prior 24 months, RB, PI, PP-R, CG-O, and MSDR have received honoraria as consultant and/or speaker for Eli-Lilly, Novartis, Teva, and Allergan/Abbvie.